Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H15F6N5O.H2O4S |
Molecular Weight | 505.392 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC3=C(F)C=C(F)C(F)=C3
InChI
InChIKey=WSJSNSFEWVZILC-SBSPUUFOSA-N
InChI=1S/C16H15F6N5O.H2O4S/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;1-5(2,3)4/h4,6,9H,1-3,5,7,23H2;(H2,1,2,3,4)/t9-;/m1./s1
Molecular Formula | H2O4S |
Molecular Weight | 98.078 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H15F6N5O |
Molecular Weight | 407.3136 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23745054
https://www.ncbi.nlm.nih.gov/pubmed/17580730
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23745054
https://www.ncbi.nlm.nih.gov/pubmed/17580730
Sitagliptin (MK-0431), chemically (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifl uorophenyl)butan-2-amine has a very high selectivity towards DPP-4, with an IC(50) of 18 nM. There is no affinity towards other DDP enzymes (DPP- 8 and DPP-9). It has been approved for the treatment of type 2 diabetes in the USA and Europe and is registered by the name Januvia (Merck Pharmaceuticals, Whitehouse Station, NJ, USA). In healthy volunteers and in patients with type 2 diabetes of different ethnic background, the tolerability of different doses given once or twice daily is good. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin. Sitagliptin is an incretin enhancer and the first marketed medication belonging to the gliptin class. In fact, no published literature exists regarding incidence or severity of hypoglycemia when sitagliptin is used off-label in combined with insulin therapy. However, is recommended to use methods to avoid hypoglycemia when using this off-label combination. Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination. Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17352677
Curator's Comment: # Merck in 1999
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL284 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17580730 |
18.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | JANUVIA Approved UseJANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1.1) Important Limitations of Use: •JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. (1.2) •JANUVIA has not been studied in patients with a history of pancreatitis. (1.2, 5.1) 1.1 Monotherapy and Combination Therapy JANUVIA® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [See Clinical Studies (14). Launch Date2006 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
950 nM |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.52 μM × h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.4 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62% |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SITAGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg single, oral Highest studied dose |
unhealthy, 14.8 years n = 8 Health Status: unhealthy Condition: type 2 diabetes mellitus Age Group: 14.8 years Sex: M+F Population Size: 8 Sources: |
Other AEs: Vomiting... |
800 mg single, oral Studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: |
healthy, 18-45 years n = 77 Health Status: healthy Age Group: 18-45 years Sex: M+F Population Size: 77 Sources: |
|
1700 mg single, oral Overdose Dose: 1700 mg Route: oral Route: single Dose: 1700 mg Sources: |
unknown, 86 years |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | 12.5% | 200 mg single, oral Highest studied dose |
unhealthy, 14.8 years n = 8 Health Status: unhealthy Condition: type 2 diabetes mellitus Age Group: 14.8 years Sex: M+F Population Size: 8 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15.0 |
no [IC50 >100 uM] | |||
Page: 15, 30 |
no [IC50 >100 uM] | no (co-administration study) Comment: results indicated that sitagliptin was not a time-dependent inhibitor of CYP3A4; sitagliptin did not meaningfully alter the pharmacokinetics of simvastatin. Page: 15, 30 |
||
Page: 6.0 |
no | |||
Page: 15.0 |
no | |||
Page: 6.0 |
no | |||
Page: 9.0 |
no | |||
Page: 15.0 |
no | no (co-administration study) Comment: sitagliptin had no inhibitory effect on the P-gp mediated transport of digoxin, verapmil, ritonavir, adn vinblastine Page: 15.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
inconclusive | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 15.0 |
no | |||
Page: 4, 42 |
yes | |||
Page: 4, 42 |
yes | |||
Page: 4, 15 |
yes | |||
Page: 4, 15 |
yes | yes (co-administration study) Comment: cyclosporin A significantly inhibited P-gp transport of sitagliptin Page: 4, 15 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 22, 23 |
PubMed
Title | Date | PubMed |
---|---|---|
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. | 2005 Summer |
|
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. | 2006 Dec |
|
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. | 2006 Dec |
|
First-in-class diabetes drug approved. | 2006 Dec 1 |
|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | 2006 Nov |
|
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. | 2006 Oct |
|
Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | 2007 |
|
Sitagliptin: a viewpoint by Itamar Raz. | 2007 |
|
Sitagliptin: a viewpoint by Mark S. Kipnes. | 2007 |
|
Sitagliptin. | 2007 |
|
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. | 2007 Apr |
|
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes]. | 2007 Apr |
|
Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. | 2007 Apr |
|
[Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2]. | 2007 Aug |
|
Type 2 diabetes: the end of clinical inertia. | 2007 Aug |
|
Type 2 diabetes drug boom: is newer better? | 2007 Aug |
|
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. | 2007 Aug |
|
Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. | 2007 Aug |
|
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. | 2007 Aug |
|
Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. | 2007 Dec 15 |
|
Incretins: a new treatment option for type 2 diabetes? | 2007 Feb |
|
Sitagliptin. | 2007 Feb |
|
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. | 2007 Feb |
|
Finding new treatments for diabetes--how many, how fast... how good? | 2007 Feb 1 |
|
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. | 2007 Jan |
|
(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. | 2007 Jan 1 |
|
New treatment for diabetes. | 2007 Jan-Feb |
|
New drugs: sitagliptin phosphate, telbivudine, and panitumumab. | 2007 Jan-Feb |
|
A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. | 2007 Jul |
|
[New concepts in the treatment of type 2 diabetes]. | 2007 Jul |
|
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. | 2007 Jul |
|
Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management. | 2007 Jul-Aug |
|
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. | 2007 Jun |
|
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. | 2007 Jun |
|
Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate). | 2007 Jun 15 |
|
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin. | 2007 Jun 15 |
|
Sitagliptin/metformin (Janumet) for type 2 diabetes. | 2007 Jun 4 |
|
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. | 2007 Mar |
|
Treatment of type 2 diabetes mellitus and the incretin system. | 2007 May |
|
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. | 2007 May |
|
Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. | 2007 May |
|
New treatments for diabetes. | 2007 May 24 |
|
New treatments for diabetes. | 2007 May 24 |
|
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. | 2007 Sep |
|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. | 2007 Sep |
|
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. | 2007 Sep |
|
Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. | 2007 Sep |
|
Sitagliptin: a novel drug for the treatment of type 2 diabetes. | 2007 Sep-Oct |
|
Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction. | 2008 Feb |
|
Dipeptidyl peptidase IV inhibitors and diabetes therapy. | 2008 Jan 1 |
Sample Use Guides
100 mg once daily. It can be taken with or without food.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23849976
Curator's Comment: Sitagliptin therapy enhances circulating angiogenic cell numbers, angiogenesis and blood flow in the critical limb ischemia area.
Adipose tissue from adult-male Fischer 344 rats were cultured in endothelial progenitor cell culture medium for 14 d with (25 μmol/L) or without sitagliptin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:31:10 GMT 2023
by
admin
on
Sat Dec 16 17:31:10 GMT 2023
|
Record UNII |
15UP896M97
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
44133341
Created by
admin on Sat Dec 16 17:31:10 GMT 2023 , Edited by admin on Sat Dec 16 17:31:10 GMT 2023
|
PRIMARY | |||
|
15UP896M97
Created by
admin on Sat Dec 16 17:31:10 GMT 2023 , Edited by admin on Sat Dec 16 17:31:10 GMT 2023
|
PRIMARY | |||
|
1169707-31-6
Created by
admin on Sat Dec 16 17:31:10 GMT 2023 , Edited by admin on Sat Dec 16 17:31:10 GMT 2023
|
PRIMARY | |||
|
100000170303
Created by
admin on Sat Dec 16 17:31:10 GMT 2023 , Edited by admin on Sat Dec 16 17:31:10 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |